Home Newsfeeds Keybanc Maintains Overweight on AvidXchange Holdings, Lowers Price Target to $10

Keybanc Maintains Overweight on AvidXchange Holdings, Lowers Price Target to $10

Keybanc analyst Josh Beck maintains AvidXchange Holdings (NASDAQ:AVDX) with a Overweight and lowers the price target from $14 to $10.

byBenzinga Newsdesk

July 7, 2022

1 minute read

Keybanc analyst Josh Beck maintains AvidXchange Holdings (NASDAQ:AVDX) with a Overweight and lowers the price target from $14 to $10.

HealthEquity Stock Climbs After Better-Than-Expected Q1 Results, Strong Forward Guidance

By Erica Kollmann

June 3, 4:32 PM

HealthEquity shares are climbing after the company reported its first-quarter financial results Monday. Here's a look at the highlights from the report.

HQY

Alaunos Therapeutics Highlights Strategic Priorities And Anticipated Portfolio Milestones For 2023; Alaunos Ended Q4 2022 With Unaudited Cash And Cash Equivalents Of ~$39.1M And Restricted Cash Of ~$13.9M

By Benzinga Newsdesk

January 9, 9:58 AM

Announcing addition of two new TCRs to the library, estimated to double the addressable market; plans to further expand TCR library using hunTR® TCR discovery platform Increasing patient enrollment to

TCRT

‘Supreme Court Probe Fails To Find Who Leaked Abortion Ruling’ – CNBC

By Benzinga Newsdesk

January 19, 3:43 PM

https://www.cnbc.com/2023/01/19/supreme-court-probe-fails-to-find-abortion-ruling-leaker.html An investigation into who leaked a bombshell Supreme Court ruling overturning the federal constitutional right to abortion weeks before it was officially released failed to identify the culprit, the court said Thursday

SPY

Who’s Leading, What’s Happening & When It Starts: Analyst Unpacks Virginia’s Cannabis Market

By Nicolas Jose Rodriguez

January 15, 2:33 PM

Virginia's impending recreational cannabis market, as analyzed by Pablo Zuanic from Zuanic & Associates, points to a promising start for medical incumbents.

CBSTF

Keybanc Maintains Overweight on AvidXchange Holdings, Lowers Price Target to $10

Related Posts

HealthEquity Stock Climbs After Better-Than-Expected Q1 Results, Strong Forward Guidance

Alaunos Therapeutics Highlights Strategic Priorities And Anticipated Portfolio Milestones For 2023; Alaunos Ended Q4 2022 With Unaudited Cash And Cash Equivalents Of ~$39.1M And Restricted Cash Of ~$13.9M

‘Supreme Court Probe Fails To Find Who Leaked Abortion Ruling’ – CNBC

Who’s Leading, What’s Happening & When It Starts: Analyst Unpacks Virginia’s Cannabis Market